Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
NVP-LCQ195 is an inhibitor of cyclin-dependent kinases (CDKs).1 It selectively inhibits Cdk5/p25, Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin A, and Cdk2/cyclin E complexes (IC50s = 1, 1, 2, 2, and 5 nM, respectively) over Cdk9/cyclin T1, Cdk3/cyclin E, Cdk6/cyclin D3, and Cdk7/cyclin H complexes (IC50s = 15, 42, 187, and 3,564 nM, respectively). NVP-LCQ195 decreases viability in a panel of 25 multiple myeloma cells (EC50s = 0.761-2.81 µM). It induces cell cycle arrest at the G0 phase and apoptosis in MM.1S multiple myeloma cells when used at a concentration of 2 µM.
WARNING This product is not for human or veterinary use.
1. Molecular and cellular effects of multi-